Amgen Inc
- Industria
- Pharmaceuticals
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 17 de junio de 1983
- Empleados
- 31.500
- Sitio web
- www.amgen.com
Rango de valoración compuesto · conservador $200–$250 / razonable $260–$320 / optimista $320–$380. A $376.26, Dentro del rango de valor intrínseco optimista · con muchas expectativas ya descontadas.
Al publicar $331.57 (21 de mayo de 2026)
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Historia
Amgen Inc. was incorporated in 1980 and completed its IPO on June 17, 1983. The company discovers, develops, manufactures, and delivers human therapeutics worldwide, operating as a single reporting segment. In October 2023 it completed the Horizon acquisition for total consideration of about $27.8 billion. Revenue grew from $25.98 billion in 2021 to $36.751 billion in 2025.
Posición en el sector
Amgen is a mature large biopharmaceutical company in the Healthcare sector, classified under Drug Manufacturers - General, with about 31,500 employees. In 2025 it reported total revenue of $36.751 billion and product sales of $35.148 billion, with 14 products exceeding $1 billion in annual sales and 18 products setting annual sales records; no single product accounted for more than 13% of product sales. By 2025 it had launched 8 biosimilars, and its capital-market peers include Bristol Myers, Regeneron, Merck, Eli Lilly, and AbbVie.
Aún no hay análisis sobre este valor en tu idioma.